Patheon appoints Michael Lytton
pharmafile | May 19, 2011 | Appointment | Manufacturing and Production | appointment, manufacturing and production
Canadian contract manufacturer Patheon has appointed Michael Lytton as executive VP, corporate development and strategy, and general counsel.
He moves to the company from Biogen, where he served as executive VP, corporate and business development, reporting to Jim Mullen – who was then Biogen’s chief executive and now holds the same role at Patheon.
Jim said” “I am so pleased that Michael has agreed to join us. He is an accomplished leader, strategist and negotiator who will bring a deep and broad understanding of the industry and proven skills to help Patheon reach its full potential. I expect that Michael will assist us in building strategic alliances with our pharmaceutical and biotechnology customers as well as emerging companies and their investors, and that he will enable us to add a range of proprietary capabilities and technologies to better serve our customers.”
Michael’s 28-year career includes extensive experience in the pharmaceutical and biotech industry. Prior to joining Biogen Idec, he was a general partner with venture capital firm Oxford Bioscience Partners and before that practiced law for 17 years specialising in representing biomedical companies.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






